The American pharmaceutical industry Pfizer posted total revenues of $25.7 billion from its product sales in the first quarter of 2022, showing a large increase of 77% over the first quarter of 2021. Net income for the first quarter this year was $7.9 billion, an increase of $61% over the same period last year.
Most of Pfizer's first-quarter revenue ($13.2 billion) came from its Covid-19 vaccine developed in collaboration with Germany's BioNTech, thanks to boosting doses in several countries and in children over five, and its new Paxlovid anti-coronavirus pill (sales of $1.5 billion), according to the UK's Guardian and the French Press Agency.
The company's revenue had doubled in 2021 to $81.3 billion, and for this year Pfizer expects record sales of $98 billion to $102 billion, with about half of that coming from Covid-19 ($32 billion vaccine and $22 billion pill).The company has distributed about 3.4 billion doses of its vaccine in 179 countries.
